Red Flags Detected

• ⚠ Controlled Company (new) — ROKIT Healthcare will retain majority voting control after the offering, limiting public stockholders' influence over significant decisions.
• ⚠ Related Party (new) — The company has no full-time employees and depends on ROKIT Healthcare for administrative, operational, and development functions, creating conflicts of interest and operational dependence.
• ⚠ Material Weakness (new) — The company acknowledges it may have material weaknesses in internal control over financial reporting, which could undermine the reliability of its financial statements.
• ⚠ Concentration (new) — ROKIT Healthcare is the sole supplier for ORP products, and Korea accounted for 67% of Q1 2026 revenue, creating significant geographic and supplier concentration.
• ⚠ Dilution (new) — New investors will experience immediate dilution of $8.56 per share, as existing stockholders paid $0.01 per share and will own 90% of the company post-offering.